Vol. 2 No. 3 (2022)
Reimbursement Recommendations

Ravulizumab (Ultomiris)

Published March 2, 2022

Key Messages

  • CADTH recommends that Ultomiris should be reimbursed by public drug plans for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) if certain conditions are met.
  • Ultomiris should only be covered to treat patients who meet existing reimbursement criteria for a similar drug, eculizumab, for the treatment of PNH. Patients already receiving eculizumab for treatment of PNH are eligible to switch to Ultomiris as long as they still have a good response to treatment with eculizumab.
  • Ultomiris should be reimbursed in a similar way to eculizumab for PNH. Also, the cost of treatment with Ultomiris should not be more than the cost of treatment with eculizumab.